Cancer remains one of the most pressing health challenges in Switzerland, affecting tens of thousands of patients each year and placing significant strain on the healthcare system. NAIPO aims to change this by introducing an integrated, AI-powered precision oncology platform. By applying advanced AI models to diagnostics, treatment personalization, and clinical decision-making, the initiative seeks to improve patient outcomes, reduce costs, and accelerate innovation in cancer care.
From a research perspective, NAIPO pushes the boundaries of medical AI. It explores pioneering approaches, including AI-assisted clinical decision support, large language models for analyzing clinical records, privacy-preserving algorithms for handling sensitive health data, and foundation models for generating predictive insights. Beyond research, the initiative focuses on real-world impact, delivering robust tools, clinical interfaces, and patient-centered applications that ensure adoption and scalability.
By fostering collaboration across the country’s hospitals, research institutes, and startups, NAIPO reinforces Switzerland’s commitment to high-quality, secure, and ethically grounded innovation in healthcare. Hospitals will drive nationwide deployment, while companies and startups will help translate research into medical AI solutions, data infrastructure, and new therapies.
We are proud to join this collaborative effort and contribute to a future where AI-driven precision oncology significantly improves the lives of patients and strengthens our healthcare system.
Explore an in-depth interview with Gunnar: Interview
Read the official press release from EPFL
